Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia
Authors:
- 22 June 2018
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (10) , 1933-1939
Abstract
To investigate the efficacy and safety of thalidomide in patients with thalassemia intermedia (TI). Patients with a confirmed diagnosis of TI who met the trial criteria and signed consent forms were prescribed oral thalidomide 50 mg qn for 3 months from February 2017. Complete blood counts, Hb analysis, and liver and kidney functions were monitored monthly during treatment and any differences were compared before and after treatment. Patients with Hb increments > 2.0 g/dL were termed main responders (MaR), and those with Hb increments between 1.0 and 2.0 g/dL as minor responders (MiR), otherwise they were termed non-responders. Relevance analysis was performed to explore parameters predicting Hb increments after treatment. Adverse effects during treatment were carefully recorded. The overall response rate (ORR = MaR + MiR) and MaR rates were 78.6 and 50% after 1 month of treatment, respectively, and 85.7 and 71.4% after 3 months treatment. At the end of the treatment period, Hb and HbF increased by 2.5 ± 1.8 g/dL and 2.5 ± 1.6 g/dL, while bilirubin, lactate dehydrogenase, and the nucleated red blood cell count (NRBC) were significantly decreased, while the reticulocyte count significantly increased. Correlation analysis showed that the Hb increments correlated significantly with the ratio of HbF before treatment (r = 0.683, P = 0.007) rather than age, Hb, reticulocyte count, and NRBC before treatment. Adverse events during treatment were mild, and drug reduction or withdrawal from the trial was not required. Thalidomide had rapid and significant effects in patients with TI, and also, it is safe and convenient. But larger scale clinical trials will be required to confirm our conclusions. Trial Registration: NCT02995707, https://www.clinicaltrials.gov/ct2/show/NCT03184844?term=thalidomide+thalassemia&rank=1 .Keywords
Funding Information
- National Natural Science Foundation of China (31201103)
- Natural Science Foundation of Guangxi, China (2015GXNSFAA139164)
- Natural Science Foundation of Guangxi, China (2014GXNSFBA118187)
This publication has 23 references indexed in Scilit:
- Genotype–phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in IranInternational Journal of Hematology, 2011
- A pilot study of subcutaneous decitabine in β-thalassemia intermediaBlood, 2011
- Ineffective hemopoietic in beta thalassemia major visualisedAmerican Journal of Hematology, 2011
- The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS)Blood, 2010
- Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH diseaseBritish Journal of Haematology, 2009
- Nucleated red blood cells and soluble transferrin receptor in thalassemia syndromes: relationship with global and ineffective erythropoiesisClinical Chemistry and Laboratory Medicine (CCLM), 2009
- Thalidomide therapy in a patient with thalassemia majorBlood Cells, Molecules, and Diseases, 2008
- Response to hydroxyurea therapy in β‐thalassemiaAmerican Journal of Hematology, 2008
- Thalidomide induces γ-globin gene expression through increased reactive oxygen species–mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesisBlood, 2007
- Clinical Observation on YiSuiShengXueGranule on Treating 156 Patients with .BETA.-Thalassemia Major and the Molecular Mechanism StudyBiological and Pharmaceutical Bulletin, 2007